– USA, MA – Crescent Biopharma, Inc., a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, announced the appointment of David Lubner to its board of directors.
About David Lubner
David Lubner is a seasoned finance executive with 30 years of experience in the life sciences industry. He served as executive vice president and CFO of Ra Pharmaceuticals. Before that, he was CFO of Tetraphase Pharmaceuticals and was previously CFO of PharMetrics. He also held the CFO position at ProScript, where Velcade®, a therapy widely used for the treatment of multiple myeloma, was discovered.
David Lubner serves on the boards of directors of Arcellx, Cargo Therapeutics, Dyne Therapeutics, and Vor Biopharma as well as several private companies. He previously served on the board of directors of Nightstar Therapeutics until it was acquired by Biogen, and Point Biopharma, until its acquisition by Eli Lilly & Company.
“With an exciting pipeline, experienced management and support from leading biotechnology investors, Crescent is well-positioned to usher in the next wave of innovation in cancer therapy,” said David Lubner. “I look forward to collaborating with Crescent’s Board and executive team to deliver potentially best-in-class therapeutics for solid tumors that can transform the standard of care for patients.”
David Lubner received his B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University.
About Crescent Biopharma
Crescent Biopharma, Inc. is a biotechnology company advancing novel precision-engineered molecules to advance care for patients with solid tumors. The Company’s pipeline of three programs harnesses validated biology to accelerate the path to market for potentially best-in-class therapeutics. Crescent’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody, and it is also advancing CR-002 and CR-003, antibody drug conjugates with topoisomerase inhibitor payloads for undisclosed targets.
Crescent is developing novel precision-engineered molecules to improve outcomes for patients with solid tumors. Crescent’s lead program, CR-001, a tetravalent PD-1 x VEGF bispecific antibody, is on track for an Investigational New Drug (IND) application submission in the fourth quarter of 2025. In October 2024, Crescent entered into an acquisition agreement with GlycoMimetics, Inc. (Nasdaq: GLYC). Following closing, which is anticipated in the second quarter of 2025, the combined company will operate under the name Crescent Biopharma and advance Crescent’s portfolio.
For more: https://www.crescentbiopharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.